Hansa Biopharma Interim report January-September 2022

/PRNewswire/ -- Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and...

Related Keywords

Barcelona ,Comunidad Autonoma De Cataluna ,Spain ,Poland ,Germany ,United States ,United Kingdom ,Belgium ,Italy ,Sweden ,France ,Scotland ,Hansa Biopharma ,Prnewswire Hansa Biopharma ,Klaus Sindahl ,Donato Spota ,Guillain Barr ,Hebron University Hospital ,European Society For Organ Transplantation ,Total Revenue ,European Society ,Organ Transplantation ,Transplant International ,Great Place ,Investigational New Drug ,Year End Report ,Interim Report ,Half Year Report ,Thursday October ,Securities Markets ,Cision Ab ,